MedTrace Logo

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

NCT01456195 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 421

Last updated 2016-04-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy and safety of TAK-875 (fasiglifam), once daily (QD), in participants with type 2 diabetes mellitus (T2DM).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo

Fasiglifam placebo-matching tablets

DRUG

Fasiglifam

Fasiglifam tablets

Sponsors & Collaborators

Principal Investigators

  • Senior Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United States
  • Argentina
  • Bulgaria
  • Guatemala
  • Hungary
  • Mexico
  • Slovakia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01456195 on ClinicalTrials.gov